Diabetes for Doctors

May 16 2024

Once-weekly basal insulin cuts HbA1c for adults with type 2 diabetes in two phase 3 trials

A once-weekly basal insulin conferred noninferior reductions in HbA1c among insulin-naive adults with type 2 diabetes and those who receive multiple daily insulin injections, according to top-line results from two phase 3 trials.
Insulin efsitora alfa (Eli Lilly) is a once-weekly basal insulin currently being investigated as part of the QWINT phase 3 trial program for adults with type 1 and type 2 diabetes. In both the QWINT-2 and QWINT-4 treat-to-target trials, once-weekly efsitora met the trials’ primary endpoints of noninferior HbA1c reductions when compared with once-daily insulins.

Read More

From Healio.com ENDOCRINOLOGY • Diabetes for Doctors • 0

May 16 2024

Close follow-up, education critical for preventing recurrence of hyperglycemic crises

NEW ORLEANS — A consensus statement on managing diabetic ketoacidosis and hyperosmolar hyperglycemic state for adults with diabetes focuses on preventing recurrence and providing people with the tools to maintain glycemic control.
During a plenary presentation at the AACE annual meeting, Guillermo E. Umpierrez, MD, professor of medicine in the division of endocrinology at Emory University School of Medicine and director of the diabetes and endocrinology section at Grady Memorial Hospital in Atlanta, discussed a new consensus guideline on the management of hyperglycemic crises for adults

Read More

From Healio.com ENDOCRINOLOGY • Diabetes for Doctors • 0

May 15 2024

Apple data: Irregular menstrual cycles may predict cardiometabolic risk

Women reporting irregular menstrual cycles with or without diagnosed polycystic ovary syndrome are more likely to have cardiometabolic conditions such as diabetes and hypertension, according to new data from the Apple Women’s Health Study.
In an analysis of more than 60,000 women who reported menstrual cycle and other hormone-related data via the Apple research app, researchers also found that longer time to menstrual cycle regularity since menarche was associated with a higher prevalence of several cardiometabolic conditions. Women with longer time to cycle regularity also tended to be

Read More

From Healio.com ENDOCRINOLOGY • Diabetes for Doctors • 0

May 13 2024

Playing sports may lower insulin resistance, reduce odds for MASLD in type 1 diabetes

Adults with type 1 diabetes who play sports have less insulin resistance and are less likely to develop metabolic dysfunction-associated steatotic liver disease, according to study findings.
“Participants performing regular exercise training — a possible proxy for healthy lifestyle — had a lower degree of insulin resistance and lower odds for [metabolic dysfunction-associated steatotic liver disease] compared to those not participating in sports,” Marieke de Vries, MD, researcher in the department of internal medicine at University Medical Center Utrecht in the

Read More

From Healio.com ENDOCRINOLOGY • Diabetes for Doctors • 0

May 13 2024

Wegovy beneficial in HFpEF regardless of diuretic use, cuts need for diuretics

In patients with the obesity phenotype of HF with preserved ejection, semaglutide 2.4 mg improved HF-related symptoms and physical limitations vs. placebo regardless of diuretic use, according to new data from the STEP-HFpEF trials.
In addition, semaglutide 2.4 mg (Wegovy, Novo Nordisk) reduced the need for diuretic use in this population compared with placebo, researchers reported at the European Society of Cardiology’s Heart Failure 2024 congress.
As Healio previously reported, in the STEP-HFpEF trial of patients with obesity-related HFpEF (defined as BMI > 30 kg/m2) but no diabetes

Read More

From Healio.com ENDOCRINOLOGY • Diabetes for Doctors • 0